Company news

Everest Medicines Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notification Letter to Registered Shareholders - Virtual Meeting Arrangements for the Extraordinary General Meeting

October 30, 2026

The Strategic Cooperation Framework Agreement

October 30, 2026

Form of proxy for the extraordinary general meeting to be held on Monday, 16 November 2026

October 30, 2026

Notice of extraordinary general meeting

October 30, 2026

(1) Continuing connected transactions in relation to the strategic cooperation framework agreement; and (2) notice of extraordinary general meeting

October 30, 2026

Book closure period for extraordinary general meeting

October 28, 2026

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

October 8, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

Terms of reference of the environmental, social and governance committee

September 28, 2026

List of directors and their roles and functions

September 28, 2026

Establishment of environmental, social and governance committee

September 28, 2026

Next Day Disclosure Return

September 28, 2026

Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults

September 3, 2026

Everest Medicines Announces Interim Results for First Half of 2026

August 18, 2026

Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026

August 5, 2026

Everest Medicines Announces Participation in Upcoming Investor Conferences

July 27, 2026

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

July 7, 2026

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

June 25, 2026

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules

June 24, 2026

Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel

June 8, 2026

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China

June 7, 2026

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market

June 4, 2026

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

June 2, 2026

Everest Medicines Signs Share Purchase Agreement with Hasten Biopharmaceuticals (Asia) Limited

April 7, 2026

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China

March 22, 2026

Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited

March 17, 2026

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call

March 16, 2026

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

March 13, 2026

Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026

March 10, 2026

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China

March 9, 2026

Everest Medicines Announces China NMPA Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis

February 6, 2026

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

February 4, 2026

Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

December 17, 2025

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

December 14, 2025

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

December 11, 2025

Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

November 20, 2025

NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

October 30, 2025

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

October 29, 2025

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

October 16, 2025

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

October 14, 2025

Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

October 12, 2025

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

October 9, 2025

Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium

September 14, 2025

Everest Medicines Announces Interim Results for First Half of 2025

August 28, 2025

Everest Medicines Announces Participation in September Investor Conferences

August 25, 2025

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis

August 15, 2025

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

August 14, 2025

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis

August 14, 2025

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

August 11, 2025

Older news releases →

Decks